ArticleCPT: pharmacometrics & systems pharmacology2026
Evaluating Preclinical-to-Human Bioavailability Classification Using Smooth ROC Curve Estimation.
Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human oral bioavailability is a critical pharmacokinetic parameter that determines systemic drug exposure, informs dose selection, and guides compound prioritization during early-stage drug development. Although animal models are routinely employed to estimate human bioavailability, interspecies physiological differences and weak correlations often limit the accuracy of direct extrapolation. As an alternative, receiver operating characteristic (ROC) analysis provides a binary classification framework to evaluate the predictive performance of animal data. However, conventional empirical ROC curves are stepwise and discontinuous, which can complicate threshold determination-especially in small-sample settings. To enhance interpretability, this study applies a previously proposed smooth ROC estimation method based on Bernstein polynomials to a curated multispecies dataset that was initially analyzed using empirical techniques. Compared to the empirical approach, the Bernstein estimator produced smoother and more visually coherent ROC curves, though it slightly underestimated the area under the curve (AUC) for species with limited sample sizes. These findings reflect a trade-off between curve smoothness and discriminatory power, underscoring the practical utility of nonparametric smoothing techniques in translational pharmacokinetic modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.